2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
2
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Interventions
pembrolizumab
409
Cyclophosphamide
398
Carboplatin
307
Gemcitabine
286
Nivolumab
276
Paclitaxel
274
Cisplatin
252
Radiotherapy
225
Dexamethasone
209
Bevacizumab
207
fludarabine
195
Docetaxel
186
Rituximab
183
Capecitabine
171
Oxaliplatin
158
Lenalidomide
157
Fluorouracil
152
Temozolomide
138
Cytarabine
135
Etoposide
128
Irinotecan
124
Cetuximab
123
fludarabine phosphate
121
Injections
118
venetoclax
116
Ipilimumab
115
Doxorubicin
114
Azacitidine
108
130-nm albumin-bound paclitaxel
108
Pemetrexed
107
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Histamine H2 Antagonists
×
Clear all
NCT05319730
2026-05-26
MK-3475-06B
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
230 enrolled